Innovating Works

COVANCE

Desconocido
IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un HORIZON EUROPE HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado
imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020 H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado
ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020 H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado
PIONEER: Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020 H2020-JTI-IMI2-2016-10-two-stage Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such...
2018-06-14 - 2023-10-31 | Financiado
PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020 H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado
Smart-4-Fabry: Smart multifunctional GLA nanoformulation for Fabry disease LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020 H2020-NMBP-2016-2017 Lysosomal storage disorders (LSD) diseases are a group of rare diseases that currently lack a definitive cure. LSD incidence is about 1:5,00...
2016-11-22 - 2020-12-31 | Financiado
SCR&TOX: Stem Cells for Relevant Efficient Extended and Normalized Toxicology LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un FP7 In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their developm...
Financiado
EUROCALIN: EUROpean consortium for antiCALINs as next generation high affinity protein therapeutics The consortium aims to develop and produce an Anticalin, a member of a novel high-affinity scaffold derived from the lipocalin protein famil...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.